The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

Richard L. Schilsky; Gary Gordon; Tona M. Gilmer; Sara A. Courtneidge; Lynn M. Matrisian; Oren Grad; William G. Nelson

doi:10.1158/1078-0432.CCR-08-1265

The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

Richard L. Schilsky, Gary Gordon, Tona M. Gilmer, Sara A. Courtneidge, Lynn M. Matrisian, Oren Grad, William G. Nelson

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

Original language	English (US)
Pages (from-to)	5685-5691
Number of pages	7
Journal	Clinical Cancer Research
Volume	14
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-08-1265
State	Published - Sep 15 2008
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-08-1265

Cite this

@article{5df9661a05664b489cfa5ce500ca9135,

title = "The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)",

abstract = "The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.",

author = "Schilsky, {Richard L.} and Gary Gordon and Gilmer, {Tona M.} and Courtneidge, {Sara A.} and Matrisian, {Lynn M.} and Oren Grad and Nelson, {William G.}",

year = "2008",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-08-1265",

language = "English (US)",

volume = "14",

pages = "5685--5691",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

AU - Schilsky, Richard L.

AU - Gordon, Gary

AU - Gilmer, Tona M.

AU - Courtneidge, Sara A.

AU - Matrisian, Lynn M.

AU - Grad, Oren

AU - Nelson, William G.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

AB - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

UR - http://www.scopus.com/inward/record.url?scp=53249111807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249111807&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1265

DO - 10.1158/1078-0432.CCR-08-1265

M3 - Review article

C2 - 18794076

AN - SCOPUS:53249111807

SN - 1078-0432

VL - 14

SP - 5685

EP - 5691

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this